—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Glaukos Corp (GKOS) — chart, structure and Closelooknet read

Pick a ticker to load its detail page.

Signals for this name

Every Closelooknet reading that exists for GKOS, from the same nightly bakes the boards use. Research diary readings, not advice.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 61/100 · S&P 500 fund at 75, bullish alignedEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-10-06
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 98th percentile of the window, +5.7% over 20 sessions. Factor regime → 2026-10-06
  • Sovereign pressure Index 0.74 · up 0.17 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-10-06
How it trades on rate days beta 0.15 to TLT · on the worst bond days it held up better than the market

How it trades on rate days

How GKOS has moved when long-dated Treasury yields rise — measured against TLT, the 20+ year Treasury fund.

  • Beta to long bonds, 1 year 0.15 — shows only a loose link to bond moves for every 1% move in TLT (20+ year Treasuries), Glaukos Corp moved 0.15% on average · correlation 0.03 · higher than 17% of US names
  • Beta, last 3 months 0.16 about the same as over the year
  • On the 10 worst bond days −0.07% on average against −0.74% for the S&P 500 the 10 sessions of the past year in which TLT fell most, i.e. long yields rose most
  • Latest of those days +0.91% TLT −1.29% that day 2026-09-24

Daily total returns from the adjusted price series; a TLT down day is a day long yields rose. Beta = the average move of the name for a 1% move in TLT. Past sensitivity, not a forecast. An investment diary, not a recommendation.

Who it is priced against Medical Devices · US · 8 names with week and year-to-date

Peer group

Medical Devices · US

This name carries no Closelooknet score, so its cohort ranks on trend state — distance to the 50- and 200-day averages — never on a score it does not have.

Compared against GKOS on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — Glaukos Corp

GKOS in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Glaukos develops and sells devices and drug therapies for eye disease, with its core work centred on glaucoma. Its main products are the iStent and iStent infinite micro-bypass devices, which open natural drainage channels to relieve pressure inside the eye, alongside iDose TR, an implant that releases pressure-lowering medicine over time. It also makes iLink, a treatment for the corneal thinning condition keratoconus, and is building platforms aimed at retinal disease and skin-applied eye drug delivery. Its customers are surgery centres, hospitals and eye specialists, reached through its own sales staff and outside distributors. It is based in Aliso Viejo, California.
Where it sits in the stack
Glaukos holds no seat in Closelooknet's index. It sits in the diary's Healthcare sleeve, in the medical-devices group, among other US makers of surgical and implant-based eye therapies.
Who it is priced against
Closelooknet's peer group draws on scored Healthcare names based in the US, including Globus Medical, Veeva Systems, Regeneron Pharmaceuticals and Vertex Pharmaceuticals; the market's closer comparison is Alcon, the larger eye-care device maker.
Why Closelooknet tracks it
Glaukos carries a Closelooknet score, with momentum the strongest module and valuation the weakest; it has no index seat and has not yet drawn a diary quote.
What the diary watches
The diary watches whether the strong momentum reading holds as the shares sit off their recent high, and whether the weak valuation module narrows as analyst forecasts move.

Glaukos Corp (GKOS) trades on US exchanges.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

The Street on this name 1 analyst action on the wire · latest: price target by BTIG, 2026-08-20

The Street on this name

Analyst actions and the latest print for GKOS from the Closelooknet wires — third-party opinions on the record, not our readings.

  • Price target BTIG — target 202 from 193 Target raised to $202 from $193 (+6.6% to spot) 2026-08-20

1 action on the analyst wire since 2026-08-13: 1 target change. Analyst wire → · Earnings wire →

FAQ · from the current data · as of 2026-10-07

Quick answers

What is Glaukos Corp (GKOS)?

Glaukos Corp trades as GKOS on the US exchange (US) in the Closelooknet research universe, as of the registry build of 2026-10-07.

Is GKOS in a Closelooknet index?

Not currently — Glaukos Corp is tracked in the Closelooknet research universe but is not a constituent of a Closelooknet functional index as of 2026-10-07.

Where does GKOS trade against its moving averages?

Pullback inside an uptrend stack: Trades -6.3% vs the 50-day and +19.2% vs the 200-day average, 15.7% below the 52-week high and +120.9% off the 52-week low. Computed from daily closes. As of 2026-10-06 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

How does Glaukos Corp compare with its peers?

Against its peer group (Medical Devices · US), Glaukos Corp (GKOS) sits 15.7% below its 52-week high, 6.3% below its 50-day average; DexCom Inc (DXCM) is 6.1% below, Smith & Nephew SNATS Inc (SNN) is 27.3% below, Pacific Biosciences of California (PACB) is 21.4% below. Put any of them next to GKOS in the chart grid (2×1 or 2×2) and the page lays the companies side by side: performance, trend, valuation, margins and our money-flow reading.

How does Glaukos Corp trade when bond yields rise?

Over the past year Glaukos Corp had a beta of 0.15 to TLT, the long-dated Treasury fund — it shows only a loose link to bond moves, higher than 17% of US names. On the 10 sessions in which long bonds fell most it moved −0.07% on average, against −0.74% for the S&P 500. The "How it trades on rate days" block on this page carries the lines.

What does Glaukos Corp do?

Glaukos develops and sells devices and drug therapies for eye disease, with its core work centred on glaucoma. Its main products are the iStent and iStent infinite micro-bypass devices, which open natural drainage channels to relieve pressure inside the eye, alongside iDose TR, an implant that releases pressure-lowering medicine over time. It also makes iLink, a treatment for the corneal thinning condition keratoconus, and is building platforms aimed at retinal disease and skin-applied eye drug delivery. Closelooknet's peer group draws on scored Healthcare names based in the US, including Globus Medical, Veeva Systems, Regeneron Pharmaceuticals and Vertex Pharmaceuticals; the market's closer comparison is Alcon, the larger eye-care device maker.

Where does Glaukos Corp sit in the AI build-out?

Glaukos holds no seat in Closelooknet's index. It sits in the diary's Healthcare sleeve, in the medical-devices group, among other US makers of surgical and implant-based eye therapies. Glaukos carries a Closelooknet score, with momentum the strongest module and valuation the weakest; it has no index seat and has not yet drawn a diary quote.

What has Wall Street done on Glaukos Corp recently?

The most recent analyst action on Glaukos Corp on the Closelooknet wire is a price target by BTIG on 2026-08-20 (target 202 from 193). 1 action on the analyst wire since 2026-08-13: 1 target change. Analyst actions are third-party opinions recorded by the wire, not Closelooknet readings. The “The Street on this name” block on this page lists the moves; the full feeds are the analyst wire and the earnings wire.

What does this page show?

A live price chart with SMA overlays and drawing tools for GKOS, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

Related in the Closelooknet universe

then Medical Devices. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.